CoChat

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Tanoli, Ziaurrehman, Aldahdooh, Jehad, Alam, Farhan, Wang, Yinyin, Seemab, Umair, Fratelli, Maddalena, Pavlis, Petr, Hajduch, Marian, Bietrix, Florence, Gribbon, Philip, Zaliani, Andrea, Hall, Matthew D, Shen, Min, Brimacombe, Kyle, Kulesskiy, Evgeny, Saarela, Jani, Wennerberg, Krister, Vähä-Koskela, Markus, Tang, Jing · 2022 · Briefings in Bioinformatics

Published version of a preprint

Cited by 16

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Chemosensitivity assays are commonly used for preclinical drug discovery and clinical trial optimization. However, data from independent assays are often discordant, largely attributed to uncharacterized variation in the experimental materials and protocols. We report here the launching of Minimal Information for Chemosensitivity Assays (MICHA), accessed via https://micha-protocol.org. Distinguished from existing efforts that are often lacking support from data integration tools, MICHA can automatically extract publicly available information to facilitate the assay annotation including: 1) compounds, 2) samples, 3) reagents and 4) data processing methods. For example, MICHA provides an integrative web server and database to obtain compound annotation including chemical structures, targets and disease indications. In addition, the annotation of cell line samples, assay protocols and literature references can be greatly eased by retrieving manually curated catalogues. Once the annotation is complete, MICHA can export a report that conforms to the FAIR principle (Findable, Accessible, Interoperable and Reusable) of drug screening studies. To consolidate the utility of MICHA, we provide FAIRified protocols from five major cancer drug screening studies as well as six recently conducted COVID-19 studies. With the MICHA web server and database, we envisage a wider adoption of a community-driven effort to improve the open access of drug sensitivity assays.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/bib/bbab350

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Hatzis, 2014, Enhancing reproducibility in cancer drug screening: how do we move forward?, Cancer Res, 74, 4016, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
  2. Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels, Nature, 533, 333, 10.1038/nature17987 · DOI · Paper page
  3. Larsson, 2020, Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens, Sci Rep, 10, 1, 10.1038/s41598-020-62848-5 · DOI · Paper page
  4. Orchard, 2011, Minimum information about a bioactive entity (MIABE), Nat Rev Drug Discov, 10, 661, 10.1038/nrd3503 · DOI · Paper page
  5. Abeyruwan, 2014, Evolving BioAssay ontology (BAO): modularization, integration and applications, J Biomed Semantics, 5, 1, 10.1186/2041-1480-5-S1-S5 · DOI
  6. Barretina, 2012, The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  7. Weston, 2020, Broad anti-coronavirus activity of food and drug administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo, J Virol, 94, 10.1128/JVI.01218-20 · DOI · Paper page
  8. Gordon, 2020, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, 583, 459, 10.1038/s41586-020-2286-9 · DOI · Paper page
  9. Touret, 2020, In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep, 10, 10.1038/s41598-020-70143-6 · DOI · Paper page
  10. Brimacombe, 2020, An OpenData portal to share COVID-19 drug repurposing data in real time, bioRxiv, 2020.06.04
  11. Ellinger, 2021, A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection, 10.1038/s41597-021-00848-4 · DOI
  12. Bolis, 2017, Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid, Ann Oncol, 28, 611, 10.1093/annonc/mdw660 · DOI
  13. Tanoli, 2018, Drug target commons 2.0: a community platform for systematic analysis of drug–target interaction profiles, Database, 2018, 1, 10.1093/database/bay083 · DOI · Paper page
  14. Tang, 2018, Drug target commons: a community effort to build a consensus Knowledge Base for drug-target interactions, Cell Chem Biol, 25, 224, 10.1016/j.chembiol.2017.11.009 · DOI · Paper page
  15. Gilson, 2016, BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology, Nucleic Acids Res, 44, D1045, 10.1093/nar/gkv1072 · DOI · Paper page
  16. Gaulton, 2016, The ChEMBL database in 2017, Nucleic Acids Res, 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
  17. Alexander, 2017, The concise guide to pharmacology 2017/18: overview, Br J Pharmacol, 174, S1–S16, 10.1111/bph.13877 · DOI · Paper page
  18. Wishart, 2006, DrugBank: a comprehensive resource for in silico drug discovery and exploration, Nucleic Acids Res, 34, D668, 10.1093/nar/gkj067 · DOI · Paper page
  19. Cichonska, 2018, Learning with multiple pairwise kernels for drug bioactivity prediction, Bioinformatics, 34, i509, 10.1093/bioinformatics/bty277 · DOI
  20. Cichonska, 2017, Computational-experimental approach to drug-target interaction mapping: a case study on kinase inhibitors, PLoS Comput Biol, 13, 10.1371/journal.pcbi.1005678 · DOI · Paper page
  21. Zeng, 2020, Network-based prediction of drug–target interactions using an arbitrary-order proximity embedded deep forest, Bioinformatics, 36, 2805, 10.1093/bioinformatics/btaa010 · DOI
  22. Tang, 2019, Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer, NPJ Syst Biol Appl, 5, 1, 10.1038/s41540-019-0098-z · DOI
  23. Cheng, 2019, Network-based prediction of drug combinations, Nat Commun, 10, 1197, 10.1038/s41467-019-09186-x · DOI · Paper page
  24. Gross, 2020, Selumetinib in children with inoperable plexiform neurofibromas, N Engl J Med, 382, 1430, 10.1056/NEJMoa1912735 · DOI · Paper page
  25. Neckers, 2012, Hsp90 molecular chaperone inhibitors: are we there yet?, Clin Cancer Res, 18, 64, 10.1158/1078-0432.CCR-11-1000 · DOI · Paper page

Cited by

See all 16

Metadata

Authors
Tanoli, Z., Aldahdooh, J., Alam, F., Wang, Y., Seemab, U., Fratelli, M., Pavlis, P., Hajduch, M., Bietrix, F., Gribbon, P., Zaliani, A., Hall, M. D., Shen, M., Brimacombe, K., Kulesskiy, E., Saarela, J., Wennerberg, K., Vähä-Koskela, M., & Tang, J.
Affiliations
  • Research Program in Systems Oncology, Faculty of medicine, University of Helsinki, Finland
  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy
  • Institute of Molecular and Translational Medicine, Czech
  • European Infrastructure for Translational Medicine, UK
  • Fraunhofer Institute for Molecular Biology and Applied Ecology, Germany
  • National Center for Advancing Translational Sciences, USA
  • Institute for Molecular Medicine Finland, University of Helsinki, Finland
  • Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Denmark
Venue
Briefings in Bioinformatics
Published
2021-09-01
Volume
23
Issue
1
ISSN
  • 1467-5463
  • 1477-4054
Cited by
16
References
9
Language
en
Funders
  • EOSC-Life (824087)
  • European Research Council (716063)
  • Academy of Finland (317680)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.